Skip to main content
. 2020 Mar 9;30:105399. doi: 10.1016/j.dib.2020.105399

Table 3.

SNPs reported by VTE GWAS in European populations and their analysis in previously reported candidate gene studies or validation studies also in European populations.

Gene SNP Type of Report No. cases/controls
(combined)
MAF (cases) OR (95% CI) P-value References
F5 rs6025 Candidate gene approach 471/474 0.01* 6.50 (1.80–23.00) (GG vs. AG) <0.05 [1]
rs4524 Candidate gene approach 1488/1439 0.25⁎⁎ 0.77 (0.68–0.87) 2.51 × 10−5 [2]
rs1018827 Validation 1040/16,936 0.07* 1.53 (1.29–1.79) (AA vs. AG) 6.53 × 10−6 [3]
rs6427196 Validation 1040/16,936 0.09* 1.51 (1.28–1.78) (CC vs. CG) 9.21 × 10−6 [3]
rs2420371Ϫ
F2 rs1799963 Candidate gene approach 471/474 <0.01* 2.80 (1.40–5.60) <0.05 [4]
rs3136516 Candidate gene approach 428/795 0.28* 1.50 (1.00–2.20) <0.05 [5]
FGB/FGA/FGG rs2066865 Candidate gene approach 471/471 0.30* 2.40 (1.50–3.90) 0.002 [6]
rs6825454 Candidate gene approach 419/1228 0.31 2.80 × 10−4 [7]
rs7659024 Validation 1040/16,936 0.30* 1.40 (1.09–1.78) (AA vs. GG) 3.03 × 10−2 [3]
rs6536024 Validation 1040/16,936 0.46* 0.23 [3]
rs7654093ф
F11 rs3756008 Candidate gene approach 1837/2204 1.27 (1.16–1.38) <0.05 [8]
rs4253399 Candidate gene approach 1488/1439 0.41⁎⁎ 1.28 (1.15–1.43) 6.33 × 10.6 [2]
rs4253417
rs4444878
rs4253416
ABO rs2519093 Candidate gene approach 1488/1439 0.24⁎⁎ 1.68 (1.48–1.91) 8.08 × 10.16 [2]
rs505922 Validation 1040/16,936 0.35* 1.78 (1.46–2.15) (CC vs. TT) 5.17 × 10−11 [3]
rs630014 Validation 1040/16,936 0.42⁎⁎ 0.75 (0.67–0.84) 2.67 × 10−7 [2]
ABO rs8176719 Validation 1040/16,936 0.42⁎⁎ 1.47 (1.32–1.64) 5.68 × 10−12 [2]
Validation 96/148 0.48 1.62 (1.09–2.38) 0.015 [9]
rs687621 Validation 1040/16,936 0.38* 1.74 (1.43–2.10) (AA vs. GG) 5.45 × 10.10 [3]
rs495828 Validation 1040/16,936 0.16* 2.09 (1.64–2.63) (GG vs. TT) 1.72 × 10.10 [3]
rs8176750
rs657152
rs529565
rs8176645Ж
C4BPB rs3813948 Validation 1433/1402 0.07 0.25 [10]
NME7 rs16861990 Validation 1040/16,936 0.06* 4.11 (2.14–7.33) (CC vs. AA) 2.90 × 10−7 [3]
PROCR rs6087685 Validation 1040/16,936 0.39* 0.92 [3]
rs34234989Ɨ
TSPAN15 rs78707713 Validation 1040/16,936 0.05* 0.77 (0.66–0.91) (TT vs. TC) 6.22 × 10−3 [3]
rs17490626Ʊ
ZFPM2 rs4602861
SLC44A2 rs2288904 Validation 1040/16,936 0.18* 0.63 (0.44–0.89) (AA vs. GG) 2.42 × 10−2 [3]
rs9797861¥
SLC19A2 rs2038024
CCDC181 rs1208134
CNTN6 rs6764623
SUSD1 rs4979078
OTUD7A rs7164569
SV2C rs3733860
FUNDC2 rs114209171
COX7A2L rs72798544
rs113092656
EPHA3 rs60942712

MAF: minor allele frequency; OR: odds ratio.

MAF values obtained from “Ensembl” database

⁎⁎

Total MAF in the report (cases and controls)

Ϫ

SNP in high LD with rs6427196, particularly for European ancestry populations (r2>0.81), according to “Ensembl” database

ф

SNP in high LD with rs2066865 for all populations according to “Ensembl” database (r2>0.81)

Ж

SNP in high LD with rs8176719, particularly for European ancestry populations (r2>0.90), according to “Ensembl” database

Ɨ

SNP in high LD with rs6087685 for all populations according to “Ensembl” database (r2>0.86, except in Kenya population)

Ʊ

SNP in high LD with rs78707713 for most populations, particularly the European ancestry populations (r2=1), according to “Ensembl” database

¥

SNP in high LD with rs2288904 for most populations, particularly the European ancestry populations (r2>0.90), according to “Ensembl” database.